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Introduction
In recent years, there has been an increasing interest in
parent/child-reported outcomes (pcros) in pediatric
rheumatology practice. Incorporation of these measures
in patient assessment is deemed important as they
reflect the parents’ and children’s perception of the dis-
ease course and the effectiveness of therapeutic inter-
ventions. Although several measures of single pcros
have been developed, to date a clinical measure that
groups all pcros used in the assessment of children with
juvenile dermatomyositis (JDM) does not exist. Such
measure would provide a physician with a thorough and
systematic overview of the patient status to be scanned
at the start of the visit. This would facilitate focus on
matters that require attention, leading to more efficient
and effective clinical care.
Objectives
To develop and test a new multidimensional question-
naire incorporating all main pcros to be used in the
assessment of children with JDM in standard clinical
care.
Methods
The Juvenile Dermatomyositis Multidimensional Assess-
ment Report (JDMAR) includes 15 parent/child-centered
measures that assess well-being, pain, functional status,
health-related quality of life, fatigue, disease activity, dis-
ease status and course, disease manifestations, side effects
of medications, therapeutic compliance, problems at
school, and satisfaction with illness outcome. The
JDMAR is proposed for use as both proxy-report and
patient self-report, with the suggested age range of 7-18
years for use as self-report.
Results
A total of 107 consecutive JDM patients (44 male, 63
female) seen in 4 pediatric rheumatology centers (2 in
Italy, 1 in UK and 1 in Croatia) were included in the
study. Median disease duration was 3,1 years (IQR:1,0-
5,8) and median age at visit was 10 years (IQR:6,4-13,6).
All parents and children reported that the questionnaire
was simple and easy to understand. Completion and scor-
ing appeared to be quick, requiring 5-10 minutes. The
proportion of parents who reported normal scores on the
various JDMAR scales are summarized in the table.
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No fatigue 73 24 (32.9) Remission 92 50 (54.3)
No disease
activity
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Conclusion
Development of the JDMAR provides a promising
approach to quantitative measurement in standard
pediatric rheumatology care. Availability of this new
instrument may foster regular use of parent/patient
questionnaires in routine practice and contribute to
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